Juno Therapeutics lags behind Gilead Sciences and Novartis in developing a CAR-T gene therapy to treat adults with an aggressive form of blood cancer — but preliminary data released Wednesday suggest that Juno’s therapy, known as JCAR017, might be the most effective.

Nearly three-quarters of patients treated with a high dose of JCAR017 were free of cancer after three months. When a lower, less effective, dose of JCAR017 is included in the analysis, the complete remission rate at three months was 50 percent, according to updated results from an ongoing clinical trial that Juno refers to as TRANSCEND.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I relapsed 10 months after receiving this Juno treatment so let us not jump on the Juno bandwagon so quick. When they eliminate chemo from their protocol and get the same 3 month response, then let us praise Juno. Juno has no patient assistance program like I have found with Merck and Keytruda. There was no one to help me deal with the side effects of the treatment at Juno. Merck has nurses to take my call and answer my questions and I have an assigned nurse to my case. Merck is really there to help me and my oncologist.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy